Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Advanced Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05042791
What this trial is testing

Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

Who this might be right for
HER2-positive Metastatic Breast Cancer
Jiangxi Provincial Cancer Hospital 362
Early research (Phase 1)Active Not RecruitingNCT05870579
What this trial is testing

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 28
Not applicableLooking for participantsNCT06856200
What this trial is testing

Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Who this might be right for
Advanced HR - Positive, HER2 - Negative Breast CancerResistant to (Neo)Adjuvant Endocrine Therapy
Fudan University 36
Large-scale testing (Phase 3)Looking for participantsNCT07062965
What this trial is testing

Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Who this might be right for
Breast Cancer
Pfizer 400
Testing effectiveness (Phase 2)Study completedNCT01783444
What this trial is testing

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 309
Large-scale testing (Phase 3)Ended earlyNCT05207709
What this trial is testing

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

Who this might be right for
Metastatic Breast Cancer
SOLTI Breast Cancer Research Group 61
Large-scale testing (Phase 3)Active Not RecruitingNCT04862663
What this trial is testing

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 893
Early research (Phase 1)Study completedNCT04541433
What this trial is testing

AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

Who this might be right for
ER+ HER2- Advanced Breast Cancer
AstraZeneca 10
Not applicableStudy completedNCT03583463
What this trial is testing

ALEXANDRIA Study Egypt

Who this might be right for
Breast Cancer
AstraZeneca 436
Testing effectiveness (Phase 2)Active Not RecruitingNCT03911973
What this trial is testing

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

Who this might be right for
TNBC - Triple-Negative Breast Cancer
Kari Wisinski 37
Not applicableLooking for participantsNCT06234137
What this trial is testing

A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer

Who this might be right for
Breast Neoplasm Female
Wang Ouchen 154
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06481956
What this trial is testing

T-DM1 Combined With CDK4/6 Inhibitor Ribociclib

Who this might be right for
HER2-positive Advanced Breast Cancer
Zheng Yabing 40
Large-scale testing (Phase 3)Looking for participantsNCT06380751
What this trial is testing

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 788
Large-scale testing (Phase 3)Study completedNCT01626222
What this trial is testing

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 301
Large-scale testing (Phase 3)Looking for participantsNCT06313086
What this trial is testing

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 442
Testing effectiveness (Phase 2)Study completedNCT00943670
What this trial is testing

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 51
Large-scale testing (Phase 3)Looking for participantsNCT06278870
What this trial is testing

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Who this might be right for
HER2-positive Metastatic Breast CancerFirst-line Treatment
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 312
Testing effectiveness (Phase 2)Study completedNCT00821886
What this trial is testing

Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
SCRI Development Innovations, LLC 60
Testing effectiveness (Phase 2)Study completedNCT04489173
What this trial is testing

TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Breast NeoplasmChemotherapy Effect
Borstkanker Onderzoek Groep 52
Testing effectiveness (Phase 2)UnknownNCT05429294
What this trial is testing

Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

Who this might be right for
HER2-positive Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University 209
Next Page